ArticleACS omega2025
Synthesis and Characterization of Highly Stable Fisetin Encapsulated in Lecithin-Chitosan-Savie Nanoparticles.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senolytic drugs, of the class of polyphenolic flavonoids, have attracted attention for a wide variety of medical applications for which they may be delivered topically, orally, and/or intravenously. However, due to their hydrophobicity and sensitivity to light and oxygen, they have been proven difficult to package and deliver. Here we report a synthesis method for encapsulated fisetin using lecithin-chitosan ionic gelation with a recently reported surfactant that is an alternative to polyethylene glycol (PEG)-containing compounds. Called "Savie" for a contraction of its components, sarcosine-Vitamin E, this surfactant allows for production of sub-100 nm nanoparticles that are bench stable for at least 10 months without aggregation. The environmentally sensitive fluorescence of fisetin allows it to be used as a tool for analysis of particle structure and stability. Absorbance, steady-state fluorescence, and fluorescence lifetime measurements alone and with quenchers indicate that a fraction of the fisetin is accessible to the surface solution and highly photooxidizable, whereas a second fraction is deeply complexed within the particle and significantly more stable. The two fractions may be distinguished from their absorbance peaks. The particles are readily taken up by cultured fibroblasts, with distinct fluorescence lifetimes occurring on the edges vs the interior of the cell. The particles show strong antioxidant activity in cells which is a combination of the effects of fisetin and Vitamin E.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.